Massivemarkets

BEAM

Beam Therapeutics Inc. Common Stock

Nasdaq · usd

$24.25-0.31 (-1.26%)
As of 9:03:05 AM EDT on Oct 23, 2026 · 15-minute delayed

Beam Therapeutics Inc. Common Stock (BEAM) trades at $24.25 (-1.26%) as of 9:03:05 AM EDT on Oct 23, 2026, +0.78% over the past month. Market cap is $2.54B, with 15.3 days to cover in short interest.

Stock performance

How Beam Therapeutics Inc. Common Stock (BEAM) stock has performed from one day to one year, with its 52-week range.

-0.41%
-$0.10 over 1D
$24.31$24.37$24.43$24.497:55 AM8:00 AM8:30 AM8:40 AM$24.30
1D
-1.13%
1W
-0.69%
1M
+0.78%
YTD
-11.40%
1Y
-12.16%
52-wk range
$20.23 – $38.26

Key statistics

Today's trading snapshot for BEAM: day range, open, previous close, volume and market cap.

Day range
$24.00 – $25.29
Open
$24.39
Prev close
$24.56
Volume
1.38M
Market cap
$2.54B
Shares out
103.29M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for Beam Therapeutics Inc. Common Stock: P/E, P/S, P/B, ROE and more.

P/E
—
P/S
16.26
P/B
2.38
P/FCF
—
ROE
-8.0%
ROA
-6.2%
Debt/Equity
0.09
Div yield
0.00%

As of Oct 22, 2026

8-K filings

Material corporate events Beam Therapeutics Inc. Common Stock has disclosed to the SEC on Form 8-K.

  • Shareholder meetingsJun 8, 2026

    On June 3, 2026, Beam Therapeutics Inc. (the "Company") held its 2026 annual meeting of stockholders (the "Annual Meeting"). The following are the voting results for the proposals considered and voted upon at the Annual Meeting.

  • Deal terminationsMar 5, 2026

    On March 2, 2026 (the "Termination Date"), Beam Therapeutics Inc. (the "Company") and Bio Palette Co., Ltd. ("Bio Palette") mutually terminated the License Agreement by and between the Company and Bio Palette dated March 27, 2019 (the "License Agreement") in connection with the planned dissolution of Bio Palette. The License Agreement was mutually terminated pursuant to a Termination Agreement by and between the Company and Bio Palette dated as of the Termination Date (the "Termination Agreement").

  • Debt activityFeb 24, 2026

    On February 24, 2026, Beam Therapeutics Inc. entered into a financing agreement providing for a senior secured term loan facility of up to $500 million, consisting of an initial draw of $100 million on the Closing Date, with potential additional draws upon FDA acceptance and approval of the Company's biologics license application for risto-cel, achievement of revenue targets, and subject to lender agreement. The Credit Facility matures on February 24, 2033 and bears interest at an annual rate equal to the 3-month SOFR plus 6.50% (subject to a 1.00% floor).

  • Deal agreementsFeb 12, 2026

    on February 9, 2026, the Company entered into a standby license agreement (the "Standby License Agreement") with Kobe and Bio Palette. Under the terms of the Standby License Agreement, if the Kobe-Bio Palette License terminates for any reason... Kobe grants, as of the effective time of such termination (the "Effective Time"), directly to the Company, an exclusive (even as to Kobe and its affiliates) license to practice the Patents of the same scope as the license granted to the Company pursuant to the Bio Palette-Beam License (the "Beam Standby License").

  • Board of directorsFeb 5, 2026

    On January 31, 2026, Carole Ho provided Beam Therapeutics Inc. (the "Company") with notice of her resignation from the Board of Directors of the Company, effective as of February 27, 2026. Dr. Ho's decision to resign did not result from any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

Dividend history and stock splits

Beam Therapeutics Inc. Common Stock's recent dividend payments and stock splits.

Dividends

  • $0.23ex-div Feb 4, 2014
  • $0.23ex-div Nov 4, 2013
  • $0.23ex-div Aug 12, 2013
  • $0.23ex-div May 6, 2013

Splits

No recent splits.

BEAM short interest

How heavily BEAM is shorted: shares short, days to cover and average daily volume.

Days to cover
15.3
Short interest
27.55M
Avg volume
1.8M

As of · reported to FINRA twice monthly.

BEAM news

The latest news and headlines about Beam Therapeutics Inc. Common Stock (BEAM).

Frequently asked questions

What is the Beam Therapeutics Inc. Common Stock (BEAM) stock price today?

Beam Therapeutics Inc. Common Stock (BEAM) is trading at $24.25 (-1.26% on the day) as of 9:03:05 AM EDT on Oct 23, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is Beam Therapeutics Inc. Common Stock?

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases.

What is the short interest in BEAM?

As of Sep 30, 2026, BEAM has 27.55M shares short and 15.3 days to cover.

Does Beam Therapeutics Inc. Common Stock (BEAM) pay a dividend?

Yes. Beam Therapeutics Inc. Common Stock (BEAM)'s most recent dividend was $0.23 per share, with an ex-dividend date of Feb 4, 2014. Full BEAM dividend history is available from the Massive API.

What exchange is BEAM listed on?

Beam Therapeutics Inc. Common Stock (BEAM) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

Build with AI

Build an analysis of BEAM with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a BEAM analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Want the most up-to-date, real-time data? Connect to the Massive API and MCP server — the source behind every number on this page — covering stocks, options, indices, currencies and futures. Docs: https://massive.com/docs/rest. Get a free API key.

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.